By altering the mRNA structure, researchers can create stable, non-immunogenic mRNA through in vitro transcription.

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...

This important manuscript provides insights into the competition between Splicing Factor 1 (SF1) and Quaking (QKI) for binding at the ACUAA branch point sequence in a model intron, regulating exon ...

Moderna, Inc. today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored ...

All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

The progress made in understanding the protein folding problem — the mystery of how a protein’s underlying amino acid ...

Scientists have successfully immortalized lip cells, creating a clinically relevant lab model that enables testing of new ...